Gofen & Glossberg’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $19.3M | Sell |
375,818
-2,519
| -0.7% | -$121K | 0.49% | 53 |
|
|
2022
Q3 | $16.6M | Sell |
378,337
-649
| -0.2% | -$31.5K | 0.47% | 55 |
|
|
2022
Q2 | $19.9M | Sell |
378,986
-3,770
| -1% | -$192K | 0.53% | 50 |
|
|
2022
Q1 | $19.8M | Sell |
382,756
-7,732
| -2% | -$401K | 0.45% | 57 |
|
|
2021
Q4 | $23.1M | Sell |
390,488
-5,406
| -1% | -$268K | 0.5% | 51 |
|
|
2021
Q3 | $17M | Sell |
395,894
-377
| -0.1% | -$16.7K | 0.4% | 63 |
|
|
2021
Q2 | $15.5M | Sell |
396,271
-15,723
| -4% | -$611K | 0.37% | 68 |
|
|
2021
Q1 | $14.9M | Sell |
411,994
-49,276
| -11% | -$1.75M | 0.38% | 68 |
|
|
2020
Q4 | $17M | Sell |
461,270
-42,492
| -8% | -$1.56M | 0.47% | 53 |
|
|
2020
Q3 | $17.5M | Buy |
503,762
+31,634
| +7% | +$1.11M | 0.54% | 50 |
|
|
2020
Q2 | $14.6M | Buy |
472,128
+8,448
| +2% | +$287K | 0.49% | 53 |
|
|
2020
Q1 | $14.4M | Sell |
463,680
-6,539
| -1% | -$223K | 0.56% | 51 |
|
|
2019
Q4 | $17.5M | Sell |
470,219
-16,732
| -3% | -$596K | 0.56% | 52 |
|
|
2019
Q3 | $16.6M | Buy |
486,951
+6,267
| +1% | +$228K | 0.56% | 51 |
|
|
2019
Q2 | $19.8M | Sell |
480,684
-7,145
| -1% | -$284K | 0.68% | 46 |
|
|
2019
Q1 | $19.7M | Sell |
487,829
-10,134
| -2% | -$406K | 0.7% | 46 |
|
|
2018
Q4 | $20.6M | Buy |
497,963
+9,654
| +2% | +$401K | 0.82% | 41 |
|
|
2018
Q3 | $20.4M | Sell |
488,309
-3,478
| -0.7% | -$134K | 0.7% | 45 |
|
|
2018
Q2 | $16.9M | Sell |
491,787
-8,997
| -2% | -$307K | 0.63% | 51 |
|
|
2018
Q1 | $16.9M | Sell |
500,784
-5,301
| -1% | -$182K | 0.63% | 51 |
|
|
2017
Q4 | $17.4M | Buy |
506,085
+3,386
| +0.7% | +$115K | 0.62% | 54 |
|
|
2017
Q3 | $17M | Sell |
502,699
-5,098
| -1% | -$164K | 0.63% | 54 |
|
|
2017
Q2 | $16.2M | Sell |
507,797
-4,505
| -0.9% | -$142K | 0.62% | 52 |
|
|
2017
Q1 | $16.6M | Sell |
512,302
-13,876
| -3% | -$437K | 0.65% | 48 |
|
|
2016
Q4 | $16.2M | Sell |
526,178
-1,295
| -0.2% | -$39.5K | 0.66% | 44 |
|
|
2016
Q3 | $16.9M | Sell |
527,473
-4,949
| -0.9% | -$165K | 0.7% | 44 |
|
|
2016
Q2 | $17.8M | Buy |
532,422
+4,629
| +0.9% | +$148K | 0.74% | 41 |
|
|
2016
Q1 | $14.8M | Buy |
527,793
+16,106
| +3% | +$460K | 0.63% | 49 |
|
|
2015
Q4 | $15.7M | Buy |
511,687
+37,038
| +8% | +$1.17M | 0.68% | 46 |
|
|
2015
Q3 | $14.1M | Buy |
474,649
+1,222
| +0.3% | +$39.2K | 0.64% | 47 |
|
|
2015
Q2 | $15.1M | Buy |
473,427
+222
| +0% | +$7.24K | 0.64% | 49 |
|
|
2015
Q1 | $15.6M | Sell |
473,205
-5,903
| -1% | -$188K | 0.67% | 44 |
|
|
2014
Q4 | $14.2M | Sell |
479,108
-1,246
| -0.3% | -$35.7K | 0.61% | 51 |
|
|
2014
Q3 | $13.5M | Sell |
480,354
-1,302
| -0.3% | -$36.5K | 0.6% | 53 |
|
|
2014
Q2 | $13.6M | Buy |
481,656
+12,541
| +3% | +$357K | 0.6% | 51 |
|
|
2014
Q1 | $14.3M | Buy |
469,115
+8,191
| +2% | +$244K | 0.67% | 46 |
|
|
2013
Q4 | $13.4M | Sell |
460,924
-7,293
| -2% | -$212K | 0.63% | 49 |
|
|
2013
Q3 | $12.8M | Sell |
468,217
-1,942
| -0.4% | -$52.8K | 0.66% | 46 |
|
|
2013
Q2 | $12.5M | Buy |
+470,159
| New | +$13M | 0.68% | 46 |
|
Other funds holding PFE
AWA
Gofen & Glossberg's PFE Position: Q4 2022 in Review
Gofen & Glossberg reduced its Pfizer (PFE) stake by 0.67% in Q4 2022, selling an estimated $121K and leaving 375,818 shares worth $19.3M. The position accounts for 0.49% of the portfolio, ranked #53.
Gofen & Glossberg first reported a position in PFE in Q2 2013 and has held it in 39 quarters since. The position peaked at $23.1M in Q4 2021. 3,265 funds tracked by Wall St. Rank hold PFE as of Q4 2022.
- Gofen & Glossberg held 375,818 shares of Pfizer worth $19.3M as of Q4 2022.
- Gofen & Glossberg sold 2,519 Pfizer shares in Q4 2022, an estimated $121K.
- Pfizer made up 0.49% of Gofen & Glossberg's portfolio in Q4 2022, its #53 holding.
- Gofen & Glossberg first reported a position in Pfizer in Q2 2013 and has held it in 39 quarters since.
- Gofen & Glossberg's Pfizer position peaked at $23.1M in Q4 2021.
- 3,265 funds tracked by Wall St. Rank held Pfizer as of Q4 2022.
Based on Gofen & Glossberg's 13F filing for Q4 2022, filed 13 Jan 2023.